BSX

SEC source: 0001225208-20-002602 · doc4.xml · derivative · entry 6

Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,538

Underlying: Common Stock · 1,845 shares

Expires 2023-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-20-002602 · doc4.xml · nonDerivative · entry 4

Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,982

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002602 · doc4.xml · nonDerivative · entry 3

Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002601 · doc4.xml · derivative · entry 5

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,459

Underlying: Common Stock · 4,153 shares

Expires 2023-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-20-002601 · doc4.xml · nonDerivative · entry 4

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,697

SEC source: 0001225208-20-002601 · doc4.xml · nonDerivative · entry 3

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-20-002600 · doc4.xml · derivative · entry 5

Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,690

Underlying: Common Stock · 3,230 shares

Expires 2023-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-20-002600 · doc4.xml · nonDerivative · entry 4

Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,625

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002600 · doc4.xml · nonDerivative · entry 3

Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,098

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002618 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,067

SEC source: 0001225208-20-002618 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,152

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002614 · doc4.xml · nonDerivative · entry 2

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,334

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002614 · doc4.xml · nonDerivative · entry 1

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,634

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002619 · doc4.xml · nonDerivative · entry 2

Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,103.99

SEC source: 0001225208-20-002619 · doc4.xml · nonDerivative · entry 1

Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,525.99

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002615 · doc4.xml · nonDerivative · entry 2

Pierce David A · CIK 0001529751 · EVP,Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,540

SEC source: 0001225208-20-002615 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP,Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,060

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002612 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,623

SEC source: 0001225208-20-002612 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,285

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002611 · doc4.xml · nonDerivative · entry 2

Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,762

SEC source: 0001225208-20-002611 · doc4.xml · nonDerivative · entry 1

Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,316

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002610 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,163,900

SEC source: 0001225208-20-002610 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,231,042

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002609 · doc4.xml · nonDerivative · entry 2

Mackey Edward F · CIK 0001632900 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,028

SEC source: 0001225208-20-002609 · doc4.xml · nonDerivative · entry 1

Mackey Edward F · CIK 0001632900 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,548

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 4

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,715

SEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 3

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,384

F2 · shares: On March 3, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002603 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,665

SEC source: 0001225208-20-002603 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,751

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002602 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,698

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002602 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,529

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002601 · doc4.xml · nonDerivative · entry 2

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,430

SEC source: 0001225208-20-002601 · doc4.xml · nonDerivative · entry 1

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,211

F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-20-002600 · doc4.xml · nonDerivative · entry 2

Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,868

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002600 · doc4.xml · nonDerivative · entry 1

Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,331

F1 · shares: On March 3, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-002210 · doc4.xml · derivative · entry 3

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,463 shares

Expires 2020-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant.

SEC source: 0001225208-20-002210 · doc4.xml · nonDerivative · entry 2

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,247

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $41.82 to $42.18, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-20-002210 · doc4.xml · nonDerivative · entry 1

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,710

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-001937 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,073

SEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 7

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt

10b5-1 filing: Not disclosed

Ownership: Indirect · By Children

Disclosed balance after: 6,777

F1 · kind: This transaction involved a gift of securities by the reporting person to his children, who share reporting person's household.

F4 · balance_after: Balance reflects gifts made in 2018, 2019, and 2020 to certain of the reporting person's children that, as of the date of this report, share his household. The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.

SEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,661

F1 · kind: This transaction involved a gift of securities by the reporting person to his children, who share reporting person's household.

SEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,746

SEC source: 0001225208-20-001555 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP,Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,899

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-001554 · doc4.xml · derivative · entry 3

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,623

Underlying: Common Stock · 9,623 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-20-001554 · doc4.xml · nonDerivative · entry 2

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,194

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-001554 · doc4.xml · nonDerivative · entry 1

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 264,817

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-001473 · doc4.xml · derivative · entry 3

Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,261

Underlying: Common Stock · 3,130 shares

Expires 2022-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-20-001473 · doc4.xml · nonDerivative · entry 2

Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,916

SEC source: 0001225208-20-001473 · doc4.xml · nonDerivative · entry 1

Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,837

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-20-000977 · doc4.xml · derivative · entry 4

Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,077 shares

Expires 2020-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase 23,077 shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant.